December 7, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (“Cassiopea”) today announced the definitive final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea (“Offer”).

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

December 3, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH PROVISIONAL FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A.

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (“Cassiopea”) today announced the provisional final results for the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructure and Market Conduct in Securities and Derivatives Trading of 19 June 2015 for all publicly held registered shares in Cassiopea (“Offer”).

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

November 26, 2021: Molecular Health GmbH

Molekulares Management des Mammakarzinoms: testen, analysieren, besprechen

Wie kann sichergestellt werden, dass Fortschritte in der Diagnostik und zielgerichteten Behandlung von Krebserkrankungen in die Patientenversorgung des Mammakarzinoms einfließen? Das war eine der zentralen Diskussionsfragen im Rahmen des Symposiums „Molekulare Diagnostik beim Mammakarzinom – Wo stehen wir auf dem Weg zur molekular stratifizierten Therapie?“ auf der Factum 2021. In seinen Ausführungen hob Referent Prof. Dr. med. Christian Jackisch, Chefarzt der Gynäkologie am Sana Klinikum Offenbach, die aus seiner Sicht drei maßgeblichen Faktoren hervor: den möglichst frühen Einsatz einer molekulargenetischen Testung, die standardisierte Interpretation mittels Softwareunterstützung und die interdisziplinäre Besprechung der Ergebnisse im molekularen Tumorboard.

Please read the whole article here

Molecular Health GmbH, News 2021

November 25, 2021: Molecular Health GmbH

Analyse-Software MH Guide unterstützt Entscheidungsfindung im Molekularen Tumorboard

Presseworkshop „Live dabei: Therapieentscheidung im molekularen Tumorboard.“
Wie Patientinnen von molekularer Diagnostik beim Mammakarzinom profitieren.

Jedes Jahr erhalten etwa 70.000 Frauen in Deutschland die Diagnose Brustkrebs.1 Viele von ihnen können ihre Behandlungschancen durch eine frühzeitige molekularpathologische Testung verbessern, denn inzwischen sind zahlreiche Genveränderungen bekannt, die hier als prognostische und prädiktive Marker für zielgerichtete Therapieoptionen zur Verfügung stehen. Die damit verbundene zunehmende Komplexität der Therapielandschaft sowie das wachsende Biomarker-Spektrum erfordern immer stärker eine interdisziplinäre Entscheidungs-findung. Auch Analysehilfsmittel zur Interpretation molekularpathologischer Ergebnisse spielen eine zunehmend wichtige Rolle. Wie die Analysesoftware MH Guide bei den wachsenden Datenmengen unterstützt und die Entscheidung im Sinne einer besseren PatientInnen-Versorgung im molekularen Tumorboard optimieren kann, wurde im Rahmen eines Presseworkshops am 17. November 2021 von Molecular Health diskutiert.

Please read the whole article here

Molecular Health GmbH, News 2021

November 19, 2021: Cosmo Pharmaceuticals NV

DETECT study shows AI assistance using GI Genius™ reduces missed polyp rate by nearly 50% on initial colonoscopy

Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced topline results from a randomized, international, multi-center study evaluating the safety and efficacy of artificial intelligence (AI) device GI Genius™ as an aid for the detection of colorectal polyps in combination with colonoscopy. The DETECT study was designed to provide evidence of the advantages of using GI Genius™ in the real-time detection of colorectal polyps and to assess if the use of GI Genius™ would decrease the miss rates of colorectal polyps and adenomas when compared to white light endoscopy.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

November 18, 2021: CureVac AG

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2021 and provided a business update.

Please read the whole article here

CureVac AG, News 2021

November 18, 2021: CureVac AG

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature. The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty® (Pfizer/BioNTech). Neutralizing antibody levels measured following full vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty® were shown to be highly comparable.

Please read the whole article here

CureVac AG, News 2021

November 18, 2021: Cosmo Pharmaceuticals NV

COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH
DEFINITIVE INTERIM RESULTS OF PUBLIC EXCHANGE OFFER FOR
ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A. AND DECLARE
THE OFFER SUCCESSFUL

Cosmo Pharmaceuticals N.V. (“Cosmo”) and Cassiopea S.p.A. (SIX: SKIN) (“Cassiopea”) today announced the following results in connection with the public exchange offer by Cosmo in Switzerland for all publicly held Cassiopea Shares (see below) (“Offer”), for which the offer period ended on 15 November 2021:

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

November 17, 2021: Cosmo Pharmaceuticals NV

Cosmo announces regulatory approval of GI Genius™ in Canada

Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that GI Genius™ has received regulatory approval in Canada.

Please read the whole article here

Cosmo Pharmaceuticals NV, News 2021

November 16, 2021: Immatics Biotechnologies GmbH

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase
Immatics to initiate three expansion cohorts for IMA203 targeting PRAME: monotherapy, combination with checkpoint inhibitor, and next-generation ACT approach
Cash and cash equivalents as well as other financial assets of $200.6 million1 (€173.2 million) as of September 30, 2021, funding company operations into 2023

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported its financial results for the quarter ended September 30, 2021, and provided a business update on its progress over the reporting period.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2021